Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERA Dosing Interval Response in HD Patients
NCT02232113Phase 4Completed
- Sponsor
- Taipei Veterans General Hospital
- Start
- Feb 2012
- Primary completion
- Jan 2013
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 4 trial of Epoetin alfa RB in anemia of chronic kidney disease (CKD-A), sponsored by Taipei Veterans General Hospital. Started Feb 2012; status: completed.
02
Drugs
Epoetin alfa RB
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02232113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232113.